AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33004541 — intervention group
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Number of subjects: 0
Study 33004541 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy/ICI combinations
Number of subjects: 0
Study 33004542 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg intravenous every 3 weeks + Bevacizumab 15 mg/kg intravenous every 3 weeks
Number of subjects: 10
Study 33004656 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic volume of 5 mL
Number of subjects: 21
Study 33004656 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic volume of 30-35 mL
Number of subjects: 21
Study 33004656 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic volume (various doses from 5 to 40 mL)
Number of subjects: 21
Study 33004656 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic volume (not specified)
Number of subjects: 21
Study 33004691 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IGF1 treatment
Number of subjects: 117
Study 33004691 — intervention group
Group type: COMPARATOR
Intervention: High plasma glucose levels
Number of subjects: 117
Study 33004691 — intervention group
Group type: COMPARATOR
Intervention: Oxygen-induced retinopathy plus hyperglycemia/hypoinsulinemia
Number of subjects: 117
Study 33004905 — intervention group
Group type: EXPERIMENTAL
Intervention: BKM120
Number of subjects: 6
Study 33004905 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC0980
Number of subjects: 6
Study 33004905 — intervention group
Group type: EXPERIMENTAL
Intervention: PI3K inhibition
Number of subjects: 6
Study 33005039 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric field-optimized, fMRI-guided TMS targeting
Number of subjects: 0
Study 33005161 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation (20 x 2-h sessions of neurocognitive and social-cognitive training, average completion of 12 hours)
Number of subjects: 111
Study 33005161 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Number of subjects: 111
Study 33005161 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 111
Study 33005432 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at highly sensitized acupoints
Number of subjects: 36
Study 33005432 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at low/non-sensitized points (control group)
Number of subjects: 36
Study 33005816 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath stacking technique plus expiratory muscle training (EMT)
Number of subjects: 42
Study 33005816 — intervention group
Group type: COMPARATOR
Intervention: Breath stacking technique alone
Number of subjects: 42
Study 33006086 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral-RNA testing
Number of subjects: 1670
Study 33006086 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal testing
Number of subjects: 1670
Study 33006086 — intervention group
Group type: EXPERIMENTAL
Intervention: Retesting of positive staff (n=33)
Number of subjects: 1670
Study 33006086 — intervention group
Group type: EXPERIMENTAL
Intervention: Postponement of procedures for positive cases (n=31)
Number of subjects: 1670
Study 33006086 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing of staff due to suspected exposure (n=67)
Number of subjects: 1670
Study 33006109 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis via NBS
Number of subjects: 0
Study 33006109 — intervention group
Group type: COMPARATOR
Intervention: Diagnosis via FH
Number of subjects: 0
Study 33006109 — intervention group
Group type: COMPARATOR
Intervention: Outpatient management
Number of subjects: 0
Study 33006109 — intervention group
Group type: COMPARATOR
Intervention: Inpatient management
Number of subjects: 0
Study 33006109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-HSCT management practices
Number of subjects: 0
Study 33006125 — intervention group
Group type: EXPERIMENTAL
Intervention: MRE values in groups 0-1, N=148
Number of subjects: 194
Study 33006125 — intervention group
Group type: EXPERIMENTAL
Intervention: High MRE values
Number of subjects: 194
Study 33006125 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical characteristics across the spectrum of liver stiffness
Number of subjects: 194
Study 33006125 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of clinical characteristics with MRE scores
Number of subjects: 194
Study 33006135 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic dermatitis (AD)
Number of subjects: 0
Study 33006561 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrive intervention (iCBT)
Number of subjects: 181
Study 33006569 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app (Drinks:Ration) with interactive features and personalized messaging
Number of subjects: 0
Study 33006569 — intervention group
Group type: COMPARATOR
Intervention: Smartphone app providing only government guidance on alcohol consumption (Control)
Number of subjects: 0
Study 33006569 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app (Drinks:Ration)
Number of subjects: 0
Study 33006749 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle Jogger (GJ)
Number of subjects: 26
Study 33006765 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 0
Study 33006765 — intervention group
Group type: COMPARATOR
Intervention: No supplementation
Number of subjects: 0
Study 33007136 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment tool for reusable duodenoscopes
Number of subjects: 1080
Study 33007265 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal fecal microbiota transplantation (FMT)
Number of subjects: 7
Study 33007265 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated CS-born infants)
Number of subjects: 7
Study 33007932 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment strategies according to local protocols in cardiac centers
Number of subjects: 0
Study 33007932 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive therapy and antithrombotic therapy including patient-tailored strategies
Number of subjects: 0
Study 33007932 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-of-life questionnaires
Number of subjects: 0
Study 33007932 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 33008303 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD) defined as GFR < 60, < 45 or < 30 ml/min/1.73 m²
Number of subjects: 2252
Study 33008303 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD) stratified by SPPB scores
Number of subjects: 2252
Study 33008303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analysis including CKD
Number of subjects: 2252
Study 33008303 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD) defined as eGFR < 45 or 30 ml/min/1.73 m²
Number of subjects: 2252
Study 33008303 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical performance assessed by SPPB
Number of subjects: 2252
Study 33008307 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Urinary Tract Symptoms (LUTS)
Number of subjects: 2256
Study 33008307 — intervention group
Group type: COMPARATOR
Intervention: Chronic Kidney Disease (CKD) with eGFR<60
Number of subjects: 2256
Study 33008307 — intervention group
Group type: COMPARATOR
Intervention: Chronic Kidney Disease (CKD) with eGFR<45
Number of subjects: 2256
Study 33008307 — intervention group
Group type: COMPARATOR
Intervention: Chronic Kidney Disease (CKD) with eGFR<30
Number of subjects: 2256
Study 33008316 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-exposed-uninfected (HEU) infants
Number of subjects: 1200
Study 33008316 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected women
Number of subjects: 1200
Study 33008316 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite primary endpoint
Number of subjects: 1200
Study 33008316 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary endpoints
Number of subjects: 1200
Study 33008359 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD stage 1-2 and 3
Number of subjects: 2252
Study 33008359 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD stage 4
Number of subjects: 2252
Study 33008359 — intervention group
Group type: EXPERIMENTAL
Intervention: All stages of CKD
Number of subjects: 2252
Study 33008394 — intervention group
Group type: EXPERIMENTAL
Intervention: A-IADL-Q-SV German
Number of subjects: 96
Study 33008401 — intervention group
Group type: EXPERIMENTAL
Intervention: New estrogen-free contraceptive pill (4 mg drospirenone, 24/4 regimen)
Number of subjects: 2500
Study 33008407 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting bioresorbable scaffolds (EE-BRS)
Number of subjects: 499
Study 33008407 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 499
Study 33008435 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication therapy for challenging behavior
Number of subjects: 34
Study 33008435 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided implementation and re-evaluation of specific behavioral measures
Number of subjects: 34
Study 33008435 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial support of MPS-families
Number of subjects: 34
Study 33008435 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-medication approaches
Number of subjects: 34
Study 33008938 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath volatile organic compounds
Number of subjects: 0
Study 33008938 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33009065 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Celiac Wheat Sensitivity (NCWS)
Number of subjects: 91
Study 33009222 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-luminance visual acuity
Number of subjects: 292
Study 33009222 — intervention group
Group type: EXPERIMENTAL
Intervention: Microperimetry
Number of subjects: 292
Study 33009222 — intervention group
Group type: COMPARATOR
Intervention: Best-corrected visual acuity
Number of subjects: 292
Study 33010149 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV direct-acting antiviral treatment
Number of subjects: 200
Study 33010149 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV testing
Number of subjects: 200
Study 33010149 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV treatment scale-up
Number of subjects: 200
Study 33010149 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV incidence
Number of subjects: 200
Study 33010162 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33010231 — intervention group
Group type: EXPERIMENTAL
Intervention: ARI-0001 cells (chimeric antigen receptor T cells targeting CD19)
Number of subjects: 0
Study 33010459 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivozanib 1.5 mg QD plus nivolumab 240 mg every 2 weeks
Number of subjects: 25
Study 33010459 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivozanib 1.5 mg QD
Number of subjects: 25
Study 33010817 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin at 1.8 mg/kg (cap at 180 mg) and nivolumab at 3 mg/kg, both intravenously every 21 days for 8 cycles
Number of subjects: 46
Study 33010817 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin and nivolumab
Number of subjects: 46
Study 33010927 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular tranexamic acid (TXA) 1 g i.v. loading dose followed by two 5 ml (0.5 g each) i.m. injections
Number of subjects: 30
Study 33010927 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular tranexamic acid (TXA)
Number of subjects: 30
Study 33010926 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anaesthesia (ED group)
Number of subjects: 60
Study 33010926 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia (non-ED group)
Number of subjects: 60
Study 33011075 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCB5-ex vivo-expanded mesenchymal stromal cells (MSCs)
Number of subjects: 9
Study 33011073 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic surgical system for liver retraction
Number of subjects: 50
Study 33011121 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-rich plaque
Number of subjects: 248
Study 33011121 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin-cap fibroatheroma (TCFA)
Number of subjects: 248
Study 33011121 — intervention group
Group type: EXPERIMENTAL
Intervention: Layered plaque
Number of subjects: 248
Study 33011121 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrophage accumulation
Number of subjects: 248
Study 33011121 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvessel presence
Number of subjects: 248
Study 33011121 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque rupture
Number of subjects: 248
Study 33011121 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus presence
Number of subjects: 248
Study 33011121 — intervention group
Group type: EXPERIMENTAL
Intervention: New layer detected in plaques with rapid progression
Number of subjects: 248
Study 33011332 — intervention group
Group type: EXPERIMENTAL
Intervention: FIBTEM maximal clot firmness (MCF) at the beginning of surgery
Number of subjects: 75
Study 33011332 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher haemoglobin concentration
Number of subjects: 75
Study 33011332 — intervention group
Group type: EXPERIMENTAL
Intervention: FIBTEM MCF at the end of surgery
Number of subjects: 75
Study 33011690 — intervention group
Group type: EXPERIMENTAL
Intervention: MINIject supraciliary drainage device implantation
Number of subjects: 25
Study 33011782 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy-only treatment (phase 3 trial)
Number of subjects: 233
Study 33011923 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec 100 units/mL, given once daily after switching from other basal insulins
Number of subjects: 459
Study 33012283 — intervention group
Group type: EXPERIMENTAL
Intervention: High-temporal-resolution PC-CMR
Number of subjects: 179
Study 33012283 — intervention group
Group type: COMPARATOR
Intervention: Doppler ultrasound
Number of subjects: 179
Study 33012283 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-CMR acquisitions
Number of subjects: 179
Study 33012343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell therapy (CD34)
Number of subjects: 133
Study 33012343 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 133
Study 33012365 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapies for Alcohol Use Disorder
Number of subjects: 0
Study 33012607 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal Tdap vaccination introduced in 2013
Number of subjects: 2315
Study 33012663 — intervention group
Group type: EXPERIMENTAL
Intervention: Using decision rules for removing outliers from FFQ data
Number of subjects: 181
Study 33012663 — intervention group
Group type: COMPARATOR
Intervention: Not removing outliers
Number of subjects: 181
Study 33012782 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (10 mg/kg Q2W) + Gefitinib (250 mg QD)
Number of subjects: 56
Study 33012782 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab and gefitinib in combination
Number of subjects: 56
Study 33012782 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 56
Study 33013294 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT)
Number of subjects: 37
Study 33013294 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 37
Study 33013302 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks sound therapy using adjusted narrow band sound
Number of subjects: 27
Study 33013302 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (HC)
Number of subjects: 27
Study 33013517 — intervention group
Group type: EXPERIMENTAL
Intervention: TRT/EMDR
Number of subjects: 0
Study 33013517 — intervention group
Group type: COMPARATOR
Intervention: TRT/CBT
Number of subjects: 0
Study 33013558 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard polychromatic blue-enriched white light (7000 K; ∼200 lx)
Number of subjects: 0
Study 33013558 — intervention group
Group type: COMPARATOR
Intervention: Warm white light (2500 K)
Number of subjects: 0
Study 33014426 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exergaming (Jintronix®) telerehabilitation intervention
Number of subjects: 10
Study 33014443 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Hyper-CL™ lens
Number of subjects: 49
Study 33014443 — intervention group
Group type: COMPARATOR
Intervention: Standard bandage contact lens (PureVision B&L)
Number of subjects: 49
Study 33014774 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33014832 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple blood-brain barrier disruptions with Temozolomide
Number of subjects: 0
Study 33015088 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy in well-nourished patients
Number of subjects: 93
Study 33015088 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy in malnourished patients
Number of subjects: 93
Study 33015088 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy-related toxicity
Number of subjects: 93
Study 33015088 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free survival
Number of subjects: 93
Study 33015088 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival at 6 months
Number of subjects: 93
Study 33015088 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 93
Study 33015088 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 93
Study 33015088 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of hospitalizations
Number of subjects: 93
Study 33015104 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal Lactoferrin administration
Number of subjects: 0
Study 33015171 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical care ultrasound (CCUS)
Number of subjects: 181
Study 33015525 — intervention group
Group type: EXPERIMENTAL
Intervention: Dickkopf-1 (DKK1) targeting in clinical trial (NCT03837353)
Number of subjects: 0
Study 33015640 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-delivered weight-loss program
Number of subjects: 27
Study 33015643 — intervention group
Group type: EXPERIMENTAL
Intervention: IFX-1 (vilobelimab)
Number of subjects: 30
Study 33015643 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (control)
Number of subjects: 30
Study 33016100 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan (S/V) treatment
Number of subjects: 782
Study 33016805 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment for symptomatic PAD
Number of subjects: 0
Study 33016887 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app exercise intervention
Number of subjects: 28
Study 33016924 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA vaccine
Number of subjects: 4
Study 33017106 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy (10-day course)
Number of subjects: 1552
Study 33017106 — intervention group
Group type: COMPARATOR
Intervention: Appendectomy
Number of subjects: 1552
Study 33017497 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab (8 mg/kg IV, day 1 every 2 weeks) plus FOLFOX4
Number of subjects: 8
Study 33017533 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated HRV tracings with up to 5 beats selected at the wrong time interval and up to 36% of BBIs removed.
Number of subjects: 10
Study 33017533 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated HRV tracings with up to 3 beats selected at the wrong time interval and up to 36% of BBIs removed.
Number of subjects: 10
Study 33017533 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated HRV tracings with more than 2 beats selected at the wrong time interval and any BBIs removed.
Number of subjects: 10
Study 33017533 — intervention group
Group type: EXPERIMENTAL
Intervention: Time domain HRV metrics.
Number of subjects: 10
Study 33017652 — intervention group
Group type: EXPERIMENTAL
Intervention: meta-GAM method for meta-analysis of generalized additive models
Number of subjects: 0
Study 33017671 — intervention group
Group type: COMPARATOR
Intervention: Stopwatch (Ultrak chronometer®)
Number of subjects: 34
Study 33017671 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic walkway (Zeno Mat®)
Number of subjects: 34
Study 33020153 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PQ)
Number of subjects: 0
Study 33020163 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioanalysis method for predicting unbound ceftriaxone concentrations
Number of subjects: 92
Study 33020163 — intervention group
Group type: EXPERIMENTAL
Intervention: Three predictive equations (empirical)
Number of subjects: 92
Study 33020485 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine
Number of subjects: 0
Study 33020594 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-119 (200 mg BID, 4 days on/3 days off, 3 out of 4 weeks)
Number of subjects: 74
Study 33020594 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-119 (150, 200, 250, 300 mg BID)
Number of subjects: 74
Study 33020594 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-119
Number of subjects: 74
Study 33020819 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-detected atrial fibrillation (AF)
Number of subjects: 7107
Study 33020819 — intervention group
Group type: COMPARATOR
Intervention: Normal ECG (Control)
Number of subjects: 7107
Study 33020819 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-detected AF
Number of subjects: 7107
Study 33020819 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly diagnosed AF
Number of subjects: 7107
Study 33020819 — intervention group
Group type: EXPERIMENTAL
Intervention: Known AF
Number of subjects: 7107
Study 33020924 — intervention group
Group type: EXPERIMENTAL
Intervention: DPYD-guided dose-individualization
Number of subjects: 0
Study 33020924 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of DPD enzyme activity
Number of subjects: 0
Study 33020924 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of pretreatment endogenous serum uracil concentrations
Number of subjects: 0
Study 33020924 — intervention group
Group type: EXPERIMENTAL
Intervention: Uracil/dihydrouracil-ratio
Number of subjects: 0